The companies Vaccibody and Roche have started a new collaboration to investigate a drug combination to treat patients with advanced cervical cancer. Both companies are members of Oslo Cancer Cluster and are involved in the development of novel cancer treatments. Martin Bonde, CEO of Vaccibody, said: “We are very pleased with this collaboration. This is […]
Author Archive for: oslocancer
This author has yet to write their bio.Meanwhile lets just say that we are proud oslocancer contributed a whooping 354 entries.
Entries by oslocancer
Fruit flies are not only annoying little insects that appear when bananas are overripe. They are also popular research tools for cancer researchers. The four pupils Kalina Topalova Casadiego, Ida Hustad Andresen, Andreas Bernhus and Dina Düring got to experience how cancer researchers look at fruit flies during their work placement in January. […]
Kuehne + Nagel joined Oslo Cancer Cluster last year. Why did a logistics company join a cluster dedicated to cancer treatment? Kuehne + Nagel is one of the world’s leading logistics providers, and pharmaceuticals are certainly a category of product that requires special care when moved between locations. This is an interview with Raphael Lømo, […]
During Cancer Crosslinks 2019, one thing was crystal clear: there is a need to include broader genomic testing into treatments for cancer patients in Norway. “We are lacking behind here in Norway!” Professor Ola Myklebost, from the Department of Clinical Science at the University of Bergen, was definitely ready for action in the panel debate at Cancer […]
The Nordic Mentor Network of Entrepreneurship (NOME) is the first pan-Nordic mentor network for lifescience start-ups. Why is it a good idea for start-ups working in cancer? Bjørn Klem has an answer. He is the General Manager of Oslo Cancer Cluster Incubator and point of contact for start-ups within the cancer field in Norway. “Start-ups […]
Today, Thursday 17 January, we broadcast LIVE from our conference Cancer Crosslinks at Oslo Cancer Cluster Innovation Park. Please join us and hear from a distinguished panel of international and Norwegian experts as they discuss the Next Wave of Precision Oncology, share new perspectives, and address the challenges and opportunities ahead. The subtitle of this […]
New work from cancer researchers at the Department of Cellular Therapy could help to streamline the development of exciting new immunotherapy approaches for treating cancer. Cancer treatments that aim to switch on a patient’s immune system to kill tumor cells – so-called immunotherapy approaches – have received much attention and encouraging results in recent years. […]
How can research help implement the next wave of precision oncology for patients? Meet the experts behind the research. These leading international experts are part of the programme at Oslo Cancer Cluster Innovation Park, 17 January. Not signed up for the 11thCancer Crosslinks yet? Join in here! Professor Naiyer Rizvi is an internationally recognized leader in the treatment […]
A prestigious EU-grant will advance OncoImmunity’s machine-learning approach to develop personalized cancer immunotherapy. The bioinformatics company OncoImmunity AS is empowering cancer immunotherapy with artificial intelligence. They use innovative software solutions to guide the discovery of neoantigen-based personalized immunotherapies and biomarkers. What does this really mean? It means that the software they have developed helps to identify […]
Kongsberg Beam Technology wants to direct the precision technology from advanced industrial control systems to hit tumors in the human body. — We want to use Norwegian spearhead technology to combat cancer, Per Håvard Kleven said from the stage as he pitched the idea of his start-up at the DNB Nordic Healthcare Conference 2018. He is […]
Contact Team >
Oslo Cancer Cluster Innovation Park opened in May 2015.
The Innovation Park brings together the oncology-value chain from basic research to industry within the Oslo-area.
Our vision is to create Europe's leading environment for education, research and industry within oncology, shortening the development time of new cancer treatments.